TY - JOUR
T1 - Cyclophosphamide or azathioprine in lupus glomerulonephritis
T2 - a controlled trial: results at 28 months
AU - Decker, J. L.
AU - Klippel, J. H.
AU - Plotz, P. H.
AU - Steinberg, A. D.
PY - 1975
Y1 - 1975
N2 - Thirty eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low dose corticosteroid treatment and have been followed for a mean of 2 1/3 yr thereafter. Of the 11 patients with unfavorable outcomes (8 deaths and 3 beginning hemodialyses), 2 occurred on cyclophosphamide, 4 on azathioprine, and 5 on prednisone only. Deaths due to infection occurred on the cytotoxics, while deaths ascribed to central nervous system lupus erythematosus occurred exclusively on prednisone only. Gradual deterioration of renal function was observed in all three groups, most frequently on prednisone only. Undesirable events, some due to drugs, were observed. At the time of reporting, the cytotoxic agents seemed to add marginally to the control of the disease; other treatment schedules should be evaluated.
AB - Thirty eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low dose corticosteroid treatment and have been followed for a mean of 2 1/3 yr thereafter. Of the 11 patients with unfavorable outcomes (8 deaths and 3 beginning hemodialyses), 2 occurred on cyclophosphamide, 4 on azathioprine, and 5 on prednisone only. Deaths due to infection occurred on the cytotoxics, while deaths ascribed to central nervous system lupus erythematosus occurred exclusively on prednisone only. Gradual deterioration of renal function was observed in all three groups, most frequently on prednisone only. Undesirable events, some due to drugs, were observed. At the time of reporting, the cytotoxic agents seemed to add marginally to the control of the disease; other treatment schedules should be evaluated.
UR - http://www.scopus.com/inward/record.url?scp=0016744128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016744128&partnerID=8YFLogxK
M3 - Article
C2 - 1106278
AN - SCOPUS:0016744128
SN - 0003-4819
VL - 83
SP - 606
EP - 615
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
IS - 5
ER -